The ORIENT-31 trial is the first prospective phase III trial to show the benefit of anti-PD-1 antibody plus chemotherapy in patients with EGFR-mutated NSCLC who have progressed after treatment with tyrosine kinase inhibitors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.